Overview
Adams Clinical runs late-phase psychiatric and neurologic clinical trials under FDA rules, using double-blind, randomized, placebo-controlled designs to test investigational drugs that have already shown initial promise. Nine full-time doctors act as neutral observers to ensure unbiased results, and coordinators with medical training help maintain data integrity through careful participant selection and standardized procedures. They provide external testing required by law (21 CFR Part 54) for the pharmaceutical industry, earning revenue from pharma companies seeking evidence of efficacy and safety. Their goal is to produce reliable, high-quality data that regulators can use to make decisions on new psychiatric and neurologic drugs, with a special focus on depression research.
Work here?Claim your company
Simplify's take
What believers are saying
- Adams added InSite in 2024, giving immediate inpatient schizophrenia and bipolar expertise.
- The Bronx Hutchinson Metro Center site opened for 7,236 square feet of research space.
- InTandem closed Fund III at $715 million in 2024, supporting more healthcare-services acquisitions.
What critics are saying
- Schizophrenia recruitment failures can delay sponsor readouts and crush site utilization in 2026.
- InTandem's 2024 buyout pressures Adams to scale fast, risking quality dilution and protocol deviations.
- If sponsor demand slips after Cobenfy-style launches, Adams' expansion-heavy model loses pricing power.
What makes Adams Clinical unique
- Adams Clinical runs late-phase CNS trials across outpatient and inpatient psychiatry, neurology, and schizophrenia.
- In 2025, Adams hired CSO Colin Sauder from Karuna's KarXT schizophrenia program.
- Its Bronx, Watertown, Harlem, and Dallas network shortens recruitment through diverse urban patient pools.
Help us improve and share your feedback! Did you find this helpful?